ALX Oncology Holdings Inc.

NASDAQ:ALXO

Biotechnology

Healthcare
$0.97 -2.12%

-$0.03 today

Market cap
$134.14M
Beta
0.45
P/E (TTM)
-0.9
EPS (TTM)
-$1.64
52W Low $0.40High $2.66

Volume 0.56M

Average 1.07M

ALXO Long-term Debt

Borrowings due after more than one year.

ALX Oncology Holdings Inc.NASDAQ: ALXO

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt remains negative

Q1 FY2026 long-term debt was $0, compared with $8.23M a year earlier.

Context

  • Long-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, down 6.8 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
Year agoMar 2025
$8.23M-100.0% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Long-term Debt vs competitors

How ALXO compares with its peers on the latest reported figures

  • ALXO's Mar 2026 long-term debt of $0 is the 3rd highest of the 8 companies compared; the peer median is $0.
  • Long-term debt amounts to 0.0% of total assets for ALXO, versus a peer median of 0.0%.
ALXO Competitors Peer median
Long-term Debt for ALXO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NKTXNkarta, Inc.Mar 2026$67.92M ——18.3%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026$34.58M ——4.7%
ALXOALX Oncology Holdings Inc.Mar 2026$0 -100.0%—0.0%
KYMRKymera Therapeutics, Inc.Jun 2026$0 ——0.0%
STOKStoke Therapeutics, Inc.Mar 2026$0 ——0.0%
ANNXAnnexon, Inc.Mar 2026$0 ——0.0%
BCYCBicycle Therapeutics plcMar 2026$0 ——0.0%
TNYATenaya Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding ALXO) $0——0.0%

Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents363.67M48.82M22.41M17.57M16.37M
Short-term Investments0217.39M160.33M110.19M28.42M
Net Receivables000892K298K
Inventory00000
Other Current Assets04.76M5.92M5.7M5.64M
Total Current Assets367.02M270.97M188.66M134.35M50.73M
Property, Plant & Equipment (Net)3.47M9.81M10.84M9.63M1.2M
Goodwill00000
Intangible Assets00000
Long-term Investments016.7M35.41M3.52M3.49M
Tax Assets00000
Other Non-current Assets9.69M9.01M7.64M267K3.63M
Total Non-current Assets13.16M35.52M53.89M13.42M8.32M
Total Assets380.18M306.49M242.55M147.78M59.05M
Account Payables3.76M8.07M8.59M4.5M4.91M
Short-term Debt000435K5.22M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities3.53M4.72M6.7M5.97M14.42M
Total Current Liabilities15.3M28.33M36M18.5M24.55M
Long-term Debt09.39M9.64M9.47M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.84M5.31M1.22M1.03M8.51M
Total Non-current Liabilities1.84M14.7M16.84M15.66M8.51M
Total Liabilities17.13M43.03M52.84M34.16M33.07M
Common Stock41K41K50K53K54K
Retained Earnings(201.99M)(325.47M)(486.27M)(621.12M)(722.82M)
Accumulated OCI(0)(845K)256K275K28K
Other Stockholders Equity00000
Minority Interest00000
Total Equity363.05M263.46M189.71M113.62M25.98M
Total Debt742K10.43M17.2M16.98M5.22M
Net Debt(362.93M)(38.39M)(5.21M)(589K)(11.16M)

ALX Oncology Holdings Inc.

NASDAQ:ALXO

Intrinsic Alpha fair value

Locked

Current Price

$0.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.